FMED Fidelity Disruptive Medicine ETF
ETF on NASDAQ (US) · Actively managed · Listing
Most notable sale · LifeStance Health Group, Inc.
LifeStance Health Group, Inc. cut by 45%
Shares went from 227,100 to 124,900 ($1.75M → $1.54M). Now 2.9% of the portfolio. Estimated trade $1.26M.
Most notable buy · Illumina, Inc.
New position in Illumina, Inc.
6,800 shares worth $1.45M. Now 2.7% of the portfolio.
Largest holding: 10x Genomics, Inc., cut 5%, 42,800 shares ($2.67M).
| Current positions Top 10 | % of book |
|---|---|
| 10x Genomics, Inc. TXG $2.67M · −5% sh | 5.0% |
| Fidelity Revere Street Trust $2.28M · −46% units | 4.2% |
| Thermo Fisher Scientific Inc TMO $1.97M · 2.5x sh | 3.7% |
| Danaher Corporation DHR $1.92M · +17% sh | 3.6% |
| Natera, Inc. NTRA $1.70M · 2x sh | 3.2% |
| argenx SE ARGX $1.65M · +17% sh | 3.1% |
| LifeStance Health Group, Inc. LFST $1.54M · −45% sh | 2.9% |
| Revolution Medicines, Inc. RVMD $1.48M · +60% sh | 2.7% |
| Illumina, Inc. ILMN $1.45M · NEW | 2.7% |
| Moderna, Inc. MRNA $1.40M · −45% sh | 2.6% |
Slices are % of holdings value. Changes ("sh" shares, "units" other holdings) are in the quantity held against May 31, 2026.
| Sectors | % of holdings value |
|---|---|
| Healthcare | 87.7% |
| Technology | 3.0% |
| Unclassified | 9.3% |
| Industries | % of holdings value |
|---|---|
| Biotechnology | 46.6% |
| Diagnostics & Research | 12.0% |
| Medical Devices | 10.2% |
| Medical Instruments & Supplies | 7.8% |
| Medical Care Facilities | 4.3% |
| Health Information Services | 2.5% |
| Software - Application | 2.5% |
| Other (4) | 5.0% |
| Unclassified | 9.3% |
| Initiations 14 | Value |
|---|---|
| Illumina, Inc. ILMN 2.7% of portfolio | $1.45M |
| West Pharmaceutical Services, Inc. WST 1.6% of portfolio | $887K |
| Twist Bioscience Corporation TWST 1.3% of portfolio | $695K |
| Dianthus Therapeutics, Inc. DNTH 0.8% of portfolio | $422K |
| Alumis Inc. ALMS 0.8% of portfolio | $410K |
| Praxis Precision Medicines, Inc. PRAX 0.7% of portfolio | $350K |
| Bruker Corporation BRKR 0.6% of portfolio | $313K |
| Braveheart Bio, Inc. BRVE 0.5% of portfolio | $255K |
| PHARVARIS BV 0.5% of portfolio | $246K |
| CG Oncology, Inc. CGON 0.4% of portfolio | $210K |
| Climb Bio, Inc. CLYM 0.4% of portfolio | $198K |
| Definium Therapeutics, Inc. DFTX 0.4% of portfolio | $191K |
| Increases 24 | Change |
|---|---|
| Thermo Fisher Scientific Inc TMO $628K → $1.97M | 2.5x |
| Natera, Inc. NTRA $584K → $1.70M | 2x |
| Revolution Medicines, Inc. RVMD $709K → $1.48M | +60% |
| Sartorius Stedim Biotech S.A. DIM $755K → $1.32M | +60% |
| Oruka Therapeutics, Inc. ORKA $58.5K → $556K | 6x |
| Repligen Corporation RGEN $308K → $760K | +69% |
| Alnylam Pharmaceuticals, Inc. ALNY $1.14M → $1.20M | +32% |
| Danaher Corporation DHR $1.40M → $1.92M | +17% |
| argenx SE ARGX $1.14M → $1.65M | +17% |
| Spyre Therapeutics, Inc. SYRE $22.1K → $232K | 8.7x |
| Relay Therapeutics, Inc. RLAY $183K → $441K | +85% |
| Roivant Sciences Ltd. ROIV $337K → $563K | +44% |
| Reductions 14 | Change |
|---|---|
| LifeStance Health Group, Inc. LFST $1.75M → $1.54M | −45% |
| Moderna, Inc. MRNA $863K → $1.40M | −45% |
| UCB SA UCB $1.94M → $825K | −50% |
| Veeva Systems Inc. VEEV $730K → $857K | −28% |
| Xenon Pharmaceuticals Inc. XENE $786K → $558K | −36% |
| Caris Life Sciences, Inc. CAI $702K → $765K | −29% |
| DexCom, Inc. DXCM $482K → $364K | −39% |
| Kymera Therapeutics, Inc. KYMR $814K → $1.01M | −15% |
| Alignment Healthcare, Inc. ALHC $511K → $297K | −33% |
| 10x Genomics, Inc. TXG $1.27M → $2.67M | −5% |
| UnitedHealth Group Incorporated UNH $922K → $818K | −13% |
| Veracyte, Inc. VCYT $631K → $519K | −12% |
| Terminations 10 | Change |
|---|---|
| Bio-Techne Corp TECH was $919K | −100% |
| Crinetics Pharmaceuticals, Inc. CRNX was $675K | −100% |
| Cytokinetics, Incorporated CYTK was $634K | −100% |
| Privia Health Group, Inc. PRVA was $605K | −100% |
| Stryker Corporation SYK was $559K | −100% |
| Lonza Group Ltd O6Z was $500K | −100% |
| NUVALENT INC was $497K | −100% |
| Insulet Corporation PODD was $451K | −100% |
| Align Technology, Inc. ALGN was $326K | −100% |
| PROCEPT BioRobotics Corporation PRCT was $175K | −100% |
The other 2 initiations
Jade Biosciences, Inc. ($159K), Annexon, Inc. ($119K)
The other 12 increases
BrightSpring Health Services, Inc. (+26%), MBX Biosciences, Inc. (+37%), Insmed Incorporated (+13%), NEWAMSTERDAM PHARMA COMPANY NV (+35%), Guardant Health, Inc. (+14%), Kestra Medical Technologies, Ltd. (+20%), Vaxcyte, Inc. (+11%), Heartflow, Inc. (+6%), Enliven Therapeutics, Inc. (+12%), Olema Oncology, Inc. (+33%), Legend Biotech Corporation (+4%), Cogent Biosciences, Inc. (+2%)
The other 2 reductions
Waystar Holding Corp. (−11%), Intuitive Surgical, Inc. (−1%)
Source: the fund's quarterly portfolio reports to the SEC, the portfolio of Aug 31, 2026 (Form N-PORT) vs the portfolio of May 31, 2026 (Form N-PORT). Percent changes are changes in the quantity held (shares, or units for holdings that are not a listed equity); dollar values are as reported at each period end. Each column is ranked by the estimated dollar size of the trade: a new or closed position at its value, otherwise the change in shares at the position's own period-end price. Where shares and price per share moved by inverse whole multiples (a split), the earlier share count is restated. Cash and money-market lines are in the book and its value but are never counted as trades. Short positions are listed as such, at their (negative) printed value.
Objective
From the summary prospectus filed Sep 28, 2026.
Fidelity® Disruptive Medicine ETF seeks long-term growth of capital.
Principal investment strategies
Normally investing at least 80% of assets in securities of disruptive medicine companies. Fidelity's disruptive strategies seek to identify innovative developments that could signal new directions for delivering products and services to customers. Generally, these companies have or are developing new or unconventional ways of doing business that could disrupt and displace incumbents over time. This may include creating, providing, or contributing to new or expanded business models, value networks, pricing, and delivery of products and services. Disruptive medicine companies are companies that have or are developing innovative ways of doing business that may be disruptive in the development, design, manufacture, or distribution of products, processes, or services in the medical field. Companies within the disruptive medicine theme include but are not limited to those companies that, in the Adviser's opinion, are engaged in robotic surgery, cell and gene therapy, genomics, rare diseases, medical devices and equipment, immunotherapy, technology-based health care platforms, precision medicine, advanced diagnostics and consumer wellness. In pursuing this investment theme, the fund may invest in companies in any economic sector. Although the fund may invest across economic sectors, the fund concentrates its investments in the health care industries. Fidelity may consider a company to fit within the disruptive theme if it meets one or more of the following criteria: (i) the company has new and/or evolving business models that have the potential to transform an industry or challenge incumbents, (ii) the company is early to market with a product or solution that has the potential to substantially impact the industry, (iii) the company possesses competitive advantages that set it apart from its competitors, (iv) the company issues patents for innovative products or services with high potential impact in the market, or (v) the company's long-term financial outlook is positioned to benefit substantially from innovation and research and development conducted by the company. Derivative instruments that provide investment exposure to the investments above or exposure to one or more market risk factors associated with such investments are included in the fund's 80% policy, consistent with the fund's investment policies and limitations with respect to investments in derivatives. Normally investing primarily in equity securities. Using fundamental analysis of factors such as each issuer's financial condition and industry position, as well as market and economic conditions, to select investments with quantitative portfolio construction. Investing in either "growth" stocks or "value" stocks or both. Investing in securities of domestic and foreign issuers.
Management and Contact
- Adviser
- Fidelity Management & Research Company LLC
- Portfolio managers
-
Michael Kim (Co-Portfolio Manager) has managed the fund since 2023.
Eddie Yoon (Co-Portfolio Manager) has managed the fund since 2025.
- [email protected]
- Website
- fidelity.com
Track Record as of Dec 31, 2025
Average annual total returns from the summary prospectus. Returns in percent; periods over a year are annualized.
| 1 Year | 5 Years | Since Inception | |
|---|---|---|---|
| Return Before Taxes | 9.69% | -0.21% | 3.37% |
| Return After Taxes on Distributions | 9.69% | -0.31% | 3.31% |
| Return After Taxes on Distributions and Sale of Fund Shares | 5.74% | -0.19% | 2.56% |
| MSCI ACWI (All Country World Index) Index (reflects no deduction for fees or expenses) | 22.71% | 11.56% | 19.90% |
| MSCI All Country World Health Care Equal Weighted Index (reflects no deduction for fees or expenses) | 11.74% | -2.23% | 3.77% |
Holdings as of Aug 31, 2026
The full portfolio as of the quarter end Aug 31, 2026, from the fund's report to the SEC (Form N-PORT, filed Oct 26, 2026), the newest we have: we do not read a daily file from this fund's website, or the filing is newer. Every line is listed: holdings we could identify link to their page, the rest (bonds, CLOs, loans, derivatives, securities we do not carry) are shown as filed, debt with its coupon and maturity; Shares is the principal amount for debt. Short positions are negative. Change is the share count against the filing of May 31, 2026.
74 lines, 68 linked, weights sum to 104.45% · Actively managed (N-CEN)
| Holding | Ticker / identifier | Type | Shares | Change | Weight | Market value |
|---|---|---|---|---|---|---|
| 10X GENOMICS INC | US88025U1097 | Equity | 42,800 | −2,200 | 5.19% | $ 2.673M |
|
Fidelity Revere Street Trust
|
US31635A3032 | Money market | 2,284,300.649 | −1,921,797.821 | 4.43% | $ 2.285M |
| THERMO FISHER SCIENTIFIC INC | US8835561023 | Equity | 3,200 | +1,924 | 3.83% | $ 1.975M |
| DANAHER CORP | US2358511028 | Equity | 9,000 | +1,325 | 3.73% | $ 1.922M |
| NATERA INC | US6323071042 | Equity | 5,280 | +2,665 | 3.30% | $ 1.7M |
| ARGENX SE | US04016X1019 | Equity | 1,600 | +235 | 3.20% | $ 1.651M |
| LIFESTANCE HEALTH GROUP INC | US53228F1012 | Equity | 124,900 | −102,200 | 3.00% | $ 1.544M |
| REVOLUTION MEDICINES INC | US76155X1000 | Equity | 7,200 | +2,696 | 2.87% | $ 1.48M |
| ILLUMINA INC | US4523271090 | Equity | 6,800 | new +6,800 | 2.82% | $ 1.453M |
| MODERNA INC | US60770K1079 | Equity | 10,000 | −8,282 | 2.72% | $ 1.403M |
| HEARTFLOW INC | US42238D1072 | Equity | 26,500 | +1,506 | 2.59% | $ 1.335M |
| SARTORIUS STEDIM BIOTECH | FR0013154002 | Equity | 5,800 | +2,167 | 2.56% | $ 1.32M |
| ALNYLAM PHARMACEUTICALS INC | US02043Q1076 | Equity | 5,000 | +1,209 | 2.33% | $ 1.203M |
| COGENT BIOSCIENCES INC | US19240Q2012 | Equity | 34,000 | +572 | 2.31% | $ 1.19M |
| INTUITIVE SURGICAL INC | US46120E6023 | Equity | 2,800 | −16 | 2.05% | $ 1.055M |
|
ASCENDIS PHARMA A/S
|
DK0060615755 | Equity | 3,865 | 0 | 1.97% | $ 1.017M |
| KYMERA THERAPEUTICS INC | US5015751044 | Equity | 8,500 | −1,500 | 1.96% | $ 1.01M |
| INSMED INC | US4576693075 | Equity | 7,775 | +900 | 1.84% | $ 947.151K |
| VAXCYTE INC | US92243G1085 | Equity | 15,571 | +1,500 | 1.83% | $ 945.783K |
|
KINIKSA PHARMACEUTICALS INTERNATIONAL PLC
|
GB00BRXB0C07 | Equity | 12,000 | 0 | 1.83% | $ 943.56K |
| EDWARDS LIFESCIENCES CORP | US28176E1082 | Equity | 10,000 | 0 | 1.76% | $ 907.5K |
| WEST PHARMACEUTICAL SVCS INC | US9553061055 | Equity | 2,600 | new +2,600 | 1.72% | $ 886.886K |
| VEEVA SYS INC | US9224751084 | Equity | 3,000 | −1,188 | 1.66% | $ 857.07K |
| UCB SA | BE0003739530 | Equity | 3,300 | −3,305 | 1.60% | $ 825.27K |
| UNITEDHEALTH GROUP INC | US91324P1021 | Equity | 2,100 | −324 | 1.59% | $ 817.761K |
| AMYLYX PHARMACEUTICALS INC | US03237H1014 | Equity | 23,554 | 0 | 1.54% | $ 794.948K |
| GUARDANT HEALTH INC | US40131M1099 | Equity | 4,975 | +600 | 1.53% | $ 791.125K |
| CARIS LIFE SCIENCES INC | US1421521071 | Equity | 30,000 | −11,991 | 1.48% | $ 764.7K |
| REPLIGEN CORP | US7599161095 | Equity | 4,200 | +1,715 | 1.47% | $ 760.116K |
| LEGEND BIOTECH CORP | US52490G1022 | Equity | 36,000 | +1,386 | 1.45% | $ 748.08K |
| BRIGHTSPRING HEALTH SERVICES INC | US10950A1060 | Equity | 12,800 | +2,613 | 1.45% | $ 747.52K |
| VIRIDIAN THERAPEUTICS INC | US92790C1045 | Equity | 31,100 | 0 | 1.40% | $ 720.276K |
| TWIST BIOSCIENCE CORP | US90184D1000 | Equity | 5,000 | new +5,000 | 1.35% | $ 695K |
| ENLIVEN THERAPEUTICS INC | US29337E1029 | Equity | 12,000 | +1,297 | 1.35% | $ 694.68K |
| BOSTON SCIENTIFIC CORP | US1011371077 | Equity | 12,185 | 0 | 1.14% | $ 588.536K |
| KESTRA MEDICAL TECHNOLOGIES INC | BMG524411052 | Equity | 22,000 | +3,600 | 1.10% | $ 566.5K |
| ROIVANT SCIENCES LTD | BMG762791017 | Equity | 16,250 | +5,000 | 1.09% | $ 562.9K |
| XENON PHARMACEUTICALS INC | CA98420N1050 | Equity | 9,266 | −5,100 | 1.08% | $ 557.999K |
| ORUKA THERAPEUTICS INC | US6876041087 | Equity | 6,000 | +5,000 | 1.08% | $ 555.72K |
| AXSOME THERAPEUTICS INC | US05464T1043 | Equity | 2,752 | 0 | 1.06% | $ 546.327K |
| DISC MEDICINE INC | US2546041011 | Equity | 6,926 | 0 | 1.06% | $ 544.73K |
| VERACYTE INC | US92337F1075 | Equity | 12,021 | −1,600 | 1.01% | $ 519.187K |
| STOKE THERAPEUTICS INC | US86150R1077 | Equity | 15,670 | 0 | 0.95% | $ 488.904K |
| WAYSTAR HOLDING CORP | US9467841055 | Equity | 18,000 | −2,187 | 0.91% | $ 471.24K |
| ELI LILLY and CO | US5324571083 | Equity | 395 | 0 | 0.89% | $ 456.908K |
| RELAY THERAPEUTICS INC | US75943R1023 | Equity | 24,000 | +11,004 | 0.86% | $ 441.12K |
| MBX BIOSCIENCES INC | US55287L1017 | Equity | 7,000 | +1,872 | 0.84% | $ 431.2K |
| DIANTHUS THERAPEUTICS INC | US2528281080 | Equity | 4,000 | new +4,000 | 0.82% | $ 422.44K |
| IRHYTHM TECHNOLOGIES INC | US4500561067 | Equity | 3,471 | 0 | 0.80% | $ 412.841K |
| ALUMIS INC | US0223071020 | Equity | 18,800 | new +18,800 | 0.80% | $ 410.028K |
| ZAI LAB LTD | US98887Q1040 | Equity | 15,273 | 0 | 0.75% | $ 388.851K |
|
NEWAMSTERDAM PHARMA COMPANY NV
|
NL00150012L7 | Equity | 15,000 | +3,878 | 0.74% | $ 380.1K |
| CYTOMX THERAPEUTICS INC | US23284F1057 | Equity | 112,069 | 0 | 0.73% | $ 376.552K |
| DEXCOM INC | US2521311074 | Equity | 4,000 | −2,533 | 0.71% | $ 364.24K |
| PRAXIS PRECISION MEDICINES INC. | US74006W2070 | Equity | 1,000 | new +1,000 | 0.68% | $ 350.3K |
| ZENAS BIOPHARMA INC | US98937L1052 | Equity | 9,817 | 0 | 0.62% | $ 317.285K |
| BRUKER CORP | US1167941087 | Equity | 5,400 | new +5,400 | 0.61% | $ 313.254K |
| ALIGNMENT HEALTHCARE INC | US01625V1044 | Equity | 22,200 | −11,178 | 0.58% | $ 297.48K |
| BRAVEHEART BIO INC | US10567X1019 | Equity | 10,000 | new +10,000 | 0.49% | $ 255K |
|
PHARVARIS BV
|
NL00150005Y4 | Equity | 7,100 | new +7,100 | 0.48% | $ 245.731K |
| SPYRE THERAPEUTICS INC | US00773J2024 | Equity | 2,600 | +2,300 | 0.45% | $ 232.258K |
| MIRUM PHARMACEUTICALS INC | US6047491013 | Equity | 2,191 | 0 | 0.42% | $ 214.828K |
| JANUX THERAPEUTICS INC | US47103J1051 | Equity | 11,754 | 0 | 0.42% | $ 214.158K |
| STRUCTURE THERAPEUTICS INC | US86366E1064 | Equity | 4,628 | 0 | 0.41% | $ 212.471K |
| CG ONCOLOGY INC | US1569441009 | Equity | 2,800 | new +2,800 | 0.41% | $ 210.448K |
| CLIMB BIO INC | US28658R1068 | Equity | 14,400 | new +14,400 | 0.38% | $ 197.712K |
| DEFINIUM THERAPEUTICS INC | CA24477V1058 | Equity | 4,800 | new +4,800 | 0.37% | $ 190.656K |
| VIKING THERAPEUTICS INC | US92686J1060 | Equity | 5,422 | 0 | 0.34% | $ 177.733K |
| UPSTREAM BIO INC | US91678A1079 | Equity | 24,900 | 0 | 0.32% | $ 164.838K |
| JADE BIOSCIENCES INC | US0080642061 | Equity | 7,426 | new +7,426 | 0.31% | $ 158.619K |
| OLEMA PHARMACEUTICALS INC | US68062P1066 | Equity | 14,950 | +3,700 | 0.30% | $ 155.929K |
|
Fidelity Revere Street Trust
|
US31635A1051 | Money market | 130,560.229 | +11,910.546 | 0.25% | $ 130.586K |
| OUTSET MEDICAL INC | US6901452069 | Equity | 34,000 | 0 | 0.25% | $ 129.88K |
| ANNEXON INC | US03589W1027 | Equity | 24,000 | new +24,000 | 0.23% | $ 118.56K |
Trades May 31, 2026 to Aug 31, 2026
Changes in shares between the fund's two newest published portfolios, cash left out. Value is the change at the line's own price in the newer portfolio.
| Holding | Ticker | Action | Before | After | Change | Value |
|---|---|---|---|---|---|---|
| ILLUMINA INC | New | — | 6,800 | +6,800 | $ 1.453M | |
| LIFESTANCE HEALTH GROUP INC | Sold | 227,100 | 124,900 | −102,200 | $ -1.263M | |
| THERMO FISHER SCIENTIFIC INC | Bought | 1,276 | 3,200 | +1,924 | $ 1.187M | |
| MODERNA INC | Sold | 18,282 | 10,000 | −8,282 | $ -1.162M | |
| BIO TECHNE CORP | Closed | 17,786 | — | −17,786 | $ -919.18K | |
| WEST PHARMACEUTICAL SVCS INC | New | — | 2,600 | +2,600 | $ 886.886K | |
| NATERA INC | Bought | 2,615 | 5,280 | +2,665 | $ 858.023K | |
| UCB SA | Sold | 6,605 | 3,300 | −3,305 | $ -826.52K | |
| TWIST BIOSCIENCE CORP | New | — | 5,000 | +5,000 | $ 695K | |
| CRINETICS PHARMACEUTICALS INC | Closed | 19,000 | — | −19,000 | $ -675.45K | |
| CYTOKINETICS INC | Closed | 8,262 | — | −8,262 | $ -634.191K | |
| PRIVIA HEALTH GROUP INC | Closed | 28,119 | — | −28,119 | $ -604.84K | |
| STRYKER CORP | Closed | 1,832 | — | −1,832 | $ -558.925K | |
| REVOLUTION MEDICINES INC | Bought | 4,504 | 7,200 | +2,696 | $ 554.217K | |
| LONZA GROUP AG | Closed | 780 | — | −780 | $ -500.047K | |
|
NUVALENT INC
|
Closed | 4,504 | — | −4,504 | $ -497.197K | |
| SARTORIUS STEDIM BIOTECH | Bought | 3,633 | 5,800 | +2,167 | $ 493.347K | |
| ORUKA THERAPEUTICS INC | Bought | 1,000 | 6,000 | +5,000 | $ 463.1K | |
| INSULET CORP | Closed | 3,112 | — | −3,112 | $ -451.053K | |
| DIANTHUS THERAPEUTICS INC | New | — | 4,000 | +4,000 | $ 422.44K | |
| ALUMIS INC | New | — | 18,800 | +18,800 | $ 410.028K | |
| PRAXIS PRECISION MEDICINES INC. | New | — | 1,000 | +1,000 | $ 350.3K | |
| VEEVA SYS INC | Sold | 4,188 | 3,000 | −1,188 | $ -339.4K | |
| ALIGN TECHNOLOGY INC | Closed | 1,863 | — | −1,863 | $ -325.932K | |
| BRUKER CORP | New | — | 5,400 | +5,400 | $ 313.254K | |
| REPLIGEN CORP | Bought | 2,485 | 4,200 | +1,715 | $ 310.381K | |
| XENON PHARMACEUTICALS INC | Sold | 14,366 | 9,266 | −5,100 | $ -307.122K | |
| CARIS LIFE SCIENCES INC | Sold | 41,991 | 30,000 | −11,991 | $ -305.651K | |
| ALNYLAM PHARMACEUTICALS INC | Bought | 3,791 | 5,000 | +1,209 | $ 290.994K | |
| DANAHER CORP | Bought | 7,675 | 9,000 | +1,325 | $ 282.967K | |
| BRAVEHEART BIO INC | New | — | 10,000 | +10,000 | $ 255K | |
|
PHARVARIS BV
|
New | — | 7,100 | +7,100 | $ 245.731K | |
| ARGENX SE | Bought | 1,365 | 1,600 | +235 | $ 242.44K | |
| DEXCOM INC | Sold | 6,533 | 4,000 | −2,533 | $ -230.655K | |
| CG ONCOLOGY INC | New | — | 2,800 | +2,800 | $ 210.448K | |
| SPYRE THERAPEUTICS INC | Bought | 300 | 2,600 | +2,300 | $ 205.459K | |
| RELAY THERAPEUTICS INC | Bought | 12,996 | 24,000 | +11,004 | $ 202.254K | |
| CLIMB BIO INC | New | — | 14,400 | +14,400 | $ 197.712K | |
| DEFINIUM THERAPEUTICS INC | New | — | 4,800 | +4,800 | $ 190.656K | |
| KYMERA THERAPEUTICS INC | Sold | 10,000 | 8,500 | −1,500 | $ -178.215K | |
| PROCEPT BIOROBOTICS CORP | Closed | 6,656 | — | −6,656 | $ -175.252K | |
| ROIVANT SCIENCES LTD | Bought | 11,250 | 16,250 | +5,000 | $ 173.2K | |
| JADE BIOSCIENCES INC | New | — | 7,426 | +7,426 | $ 158.619K | |
| BRIGHTSPRING HEALTH SERVICES INC | Bought | 10,187 | 12,800 | +2,613 | $ 152.599K | |
| ALIGNMENT HEALTHCARE INC | Sold | 33,378 | 22,200 | −11,178 | $ -149.785K | |
| 10X GENOMICS INC | Sold | 45,000 | 42,800 | −2,200 | $ -137.39K | |
| UNITEDHEALTH GROUP INC | Sold | 2,424 | 2,100 | −324 | $ -126.169K | |
| ANNEXON INC | New | — | 24,000 | +24,000 | $ 118.56K | |
| MBX BIOSCIENCES INC | Bought | 5,128 | 7,000 | +1,872 | $ 115.315K | |
| INSMED INC | Bought | 6,875 | 7,775 | +900 | $ 109.638K | |
|
NEWAMSTERDAM PHARMA COMPANY NV
|
Bought | 11,122 | 15,000 | +3,878 | $ 98.269K | |
| GUARDANT HEALTH INC | Bought | 4,375 | 4,975 | +600 | $ 95.412K | |
| KESTRA MEDICAL TECHNOLOGIES INC | Bought | 18,400 | 22,000 | +3,600 | $ 92.7K | |
| VAXCYTE INC | Bought | 14,071 | 15,571 | +1,500 | $ 91.11K | |
| HEARTFLOW INC | Bought | 24,994 | 26,500 | +1,506 | $ 75.887K | |
| ENLIVEN THERAPEUTICS INC | Bought | 10,703 | 12,000 | +1,297 | $ 75.083K | |
| VERACYTE INC | Sold | 13,621 | 12,021 | −1,600 | $ -69.104K | |
| WAYSTAR HOLDING CORP | Sold | 20,187 | 18,000 | −2,187 | $ -57.256K | |
| OLEMA PHARMACEUTICALS INC | Bought | 11,250 | 14,950 | +3,700 | $ 38.591K | |
| LEGEND BIOTECH CORP | Bought | 34,614 | 36,000 | +1,386 | $ 28.801K | |
| COGENT BIOSCIENCES INC | Bought | 33,428 | 34,000 | +572 | $ 20.02K | |
| INTUITIVE SURGICAL INC | Sold | 2,816 | 2,800 | −16 | $ -6,029.76 |
Podcast Mentions
Sign up to see podcast mentions and sentiment
Sign Up